Table 2.
Concentrations of CXCL9, CXCL10, and CXCL11 in the Plasma of Patients with Chronic Hepatitis C During Treatment with Pegylated Interferon Alpha 2a and Ribavirin Based on the Virological Response
| |
Concentrations of plasma chemokines in patients with chronic hepatitis C based on the response to treatment with PEG IFN-α2a and ribavirin (pg/mL, median, range) |
|
|---|---|---|
| Chemokines | SVR, n=26 patients | Non-SVR, n=20 |
| CXCL9 | ||
| Baseline | 171.5 (52–485) | 200 (113–442) |
| 4 weeks | 118.5 (36–399) | 176 (126–1,990) |
| 12 weeks | 153.5 (35–425) | 214 (92–290) |
| 24 weeks | 191.5 (30–510) | 298 (84–583) |
| CXCL10 | ||
| Baseline | 185 (63–518) | 395.5 (111–926) |
| 4 weeks | 156 (92–396) | 424 (90–815) |
| 12 weeks | 199 (105–780) | 277.5 (108–674) |
| 24 weeks | 202 (80–650) | 272 (76–514) |
| CXCL11 | ||
| Baseline | 109 (0–499) | 127.5 (77–341) |
| 4 weeks | 96.5 (0–211) | 135.5 (94–304) |
| 12 weeks | 97.5 (5–267) | 120.5 (81–167) |
| 24 weeks | 114 (82–267) | 127 (81–203) |
Differences in the CXCL9 and CXCL10 concentrations between SVR and non-SVR groups were statistically significant (P=0.002 and P<0.0001, respectively).
The difference in the CXCL11 concentration between SVR and non-SVR groups was not statistically significant (P=0.143).
PEG IFN-α2a, pegylated interferon alpha 2a.